Radiographic and α-fetoprotein response predict pathologic complete response to immunotherapy plus a TKI in hepatocellular carcinoma: a multicenter study
Cheng Huang,
Xiao-Dong Zhu,
Ying-Hao Shen,
Bin Xu,
Dong Wu,
Yuan Ji,
Ling-Li Chen,
Tian-Qiang Song,
Wei Zhang,
Zhi-Ming Zeng,
Hua-Sheng Huang,
Kui Wang,
Lan-Qing Huang,
Yong-Jun Chen,
Yu-Chen Yang,
Le-Du Zhou,
Guo Long,
Hai-Tao Zhao,
Yun-Chao Wang,
Ning-Ling Ge,
Yi Chen,
Chang-Jun Tan,
Jian Zhou,
Jia Fan,
Hui-Chuan Sun
Affiliations
Cheng Huang
Department of Liver Surgery and Transplantation, Liver Cancer Institute and Zhongshan Hospital, Fudan University
Xiao-Dong Zhu
Department of Liver Surgery and Transplantation, Liver Cancer Institute and Zhongshan Hospital, Fudan University
Ying-Hao Shen
Department of Liver Surgery and Transplantation, Liver Cancer Institute and Zhongshan Hospital, Fudan University
Bin Xu
Department of Liver Surgery and Transplantation, Liver Cancer Institute and Zhongshan Hospital, Fudan University
Dong Wu
Department of Radiology, Zhongshan Hospital, Fudan University
Yuan Ji
Department of Pathology, Zhongshan Hospital, Fudan University
Ling-Li Chen
Department of Pathology, Zhongshan Hospital, Fudan University
Tian-Qiang Song
Department of Hepatobiliary, Oncology Key Laboratory of Cancer Prevention and Therapy, National Clinical Research Center of Cancer, Tianjin Medical University Cancer Institute and Hospital
Wei Zhang
Department of Hepatobiliary, Oncology Key Laboratory of Cancer Prevention and Therapy, National Clinical Research Center of Cancer, Tianjin Medical University Cancer Institute and Hospital
Zhi-Ming Zeng
Department of Medical Oncology, The First Affiliated Hospital of Guangxi Medical University
Hua-Sheng Huang
Department of Medical Oncology, The First Affiliated Hospital of Guangxi Medical University
Kui Wang
Department of Hepatic Surgery II, Eastern Hepatobiliary Surgery Hospital, Navy Medical University
Lan-Qing Huang
Department of Hepatic Surgery II, Eastern Hepatobiliary Surgery Hospital, Navy Medical University
Yong-Jun Chen
Department of Hepatobiliary Surgery, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine
Yu-Chen Yang
Department of Hepatobiliary Surgery, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine
Le-Du Zhou
Department of General Surgery, Xiangya Hospital, Central South University
Guo Long
Department of General Surgery, Xiangya Hospital, Central South University
Hai-Tao Zhao
Department of Liver Surgery, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College
Yun-Chao Wang
Department of Liver Surgery, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College
Ning-Ling Ge
Department of Hepatic Oncology, Liver Cancer Institute and Zhongshan Hospital, Fudan University
Yi Chen
Department of Hepatic Oncology, Liver Cancer Institute and Zhongshan Hospital, Fudan University
Chang-Jun Tan
Department of Liver Surgery and Transplantation, Liver Cancer Institute and Zhongshan Hospital, Fudan University
Jian Zhou
Department of Liver Surgery and Transplantation, Liver Cancer Institute and Zhongshan Hospital, Fudan University
Jia Fan
Department of Liver Surgery and Transplantation, Liver Cancer Institute and Zhongshan Hospital, Fudan University
Hui-Chuan Sun
Department of Liver Surgery and Transplantation, Liver Cancer Institute and Zhongshan Hospital, Fudan University
Abstract Background Pathologic complete response (pCR) following preoperative systemic therapy is associated with improved outcomes after subsequent liver transplant/resection in hepatocellular carcinoma (HCC). However, the relationship between radiographic and histopathological response remains unclear. Methods We retrospectively examined patients with initially unresectable HCC who received tyrosine kinase inhibitor (TKI) plus anti–programmed death 1 (PD-1) therapy before undergoing liver resection between March 2019 and September 2021 across 7 hospitals in China. Radiographic response was evaluated using mRECIST. A pCR was defined as no viable tumor cells in resected samples. Results We included 35 eligible patients, of whom 15 (42.9%) achieved pCR after systemic therapy. After a median follow-up of 13.2 months, tumors recurred in 8 non-pCR and 1 pCR patient. Before resection, there were 6 complete responses, 24 partial responses, 4 stable disease cases, and 1 progressive disease case, per mRECIST. Predicting pCR by radiographic response yielded an area under the receiver operating characteristic curve (AUC) of 0.727 (95% CI: 0.558–0.902), with an optimal cutoff value of 80% reduction in the enhanced area in MRI (called major radiographic response), which had a 66.7% sensitivity, 85.0% specificity, and a 77.1% diagnostic accuracy. When radiographic response was combined with α-fetoprotein response, the AUC was 0.926 (95% CI: 0.785–0.999); the optimal cutoff value was 0.446, which had a 91.7% sensitivity, 84.6%, specificity, and an 88.0% diagnostic accuracy. Conclusions In patients with unresectable HCC receiving combined TKI/anti–PD 1 therapy, major radiographic response alone or combined with α-fetoprotein response may predict pCR.